Access to GLP-1 receptor agonists for weight loss varies significantly between the US and three other countries.
In a comparative analysis, disparities in costs and prescription rates highlight unequal access across the four regions.
Evaluation of glucagon-like peptide 1 (GLP-1) treatment reveals important differences in utilization trends and healthcare policies across nations in 2023. The implications of these disparities may affect patient outcomes and treatment accessibility.
Resumen
This Viewpoint compares use and costs of glucagon-like peptide 1 (GLP-1) receptor agonists for weight loss between the US and 3 other peer countries.